Targeting BRD4 via BET inhibitors or proteolysis-targeting chimera (PROTAC) degraders suppresses prostate cancer development, and clinical evaluation of BRD4 inhibitors is under way in patients with castration-resistant prostate cancer (NCT02711956, NCT03150056) (61–63). This evidence concerns the gene DNER and prostate cancer.